Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergent BioSolutions Takes Out Troubled Trubion For $97 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.

You may also be interested in...



Biotech Backers Learn To Live With Exit-By-Earn-Out

Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?

Facet Says Yes To Abbott's $720 Million Buyout Offer

The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.

Trubion Finds Kindred Spirit in Facet For Co-Development And Commercialization

Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel